The competitive moat in metabolic medicine is shifting from raw weight loss to muscle preservation.
To avoid long-term strength loss and metabolic rebounds, drug developers must shift focus from total weight reduction toward maintaining lean muscle mass.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Modern clinical trials are evaluating post-bariatric weight loss quality to ensure body fat is reduced without sacrificial muscle decline.
The EMBRAZE trial demonstrates that pairing muscle-preserving myostatin inhibitors with GLP-1s is key to solving long-term strength loss and metabolic rebounds.
Established drugmakers must leverage precise MRI body composition data to defend their efficacy claims against higher-potency competitors.